What Causes a False Positive for Fentanyl?

Several common prescription medications, over-the-counter drugs, and even the cutoff threshold chosen by the testing laboratory can trigger a false-positive fentanyl result on a urine drug screen. The most frequently documented culprits include certain antipsychotic medications, the antidepressant trazodone, and the blood pressure drug labetalol. The problem stems from how the initial screening tests work: they rely on antibodies that can mistake structurally similar molecules for fentanyl, and the list of substances that fool these antibodies keeps growing as researchers investigate.

Why Screening Tests Get Fooled

The standard first step in drug testing for fentanyl is an immunoassay, which uses antibodies designed to latch onto fentanyl or its metabolite norfentanyl. When one of these antibodies encounters a molecule that shares enough of fentanyl’s shape, it binds to it anyway, and the test registers a positive result. This is called cross-reactivity, and it is a fundamental limitation of every antibody-based test, not a flaw in any one product. The antibody does not “know” it grabbed the wrong molecule; it simply responded to a structural resemblance.

One study evaluating a fentanyl immunoassay found that while the test achieved perfect sensitivity (catching every true positive), its specificity was only 86%, meaning roughly one in seven positive results was actually false. Five of the seven false positives in that study were caused by risperidone and its metabolite 9-hydroxyrisperidone.

1PubMed. Cross-reactivity of acetylfentanyl and risperidone with a fentanyl immunoassay

This matters because immunoassays are the frontline screening tool used in hospitals, addiction treatment programs, probation offices, and workplace testing. When the screening test reads positive, a second, more precise confirmation test using mass spectrometry should follow. But in many real-world settings, especially when results are needed quickly or resources are limited, that confirmatory step gets skipped or delayed.

Antipsychotics and Antidepressants

The medications most consistently linked to false-positive fentanyl results are antipsychotic drugs in the risperidone family. Risperidone itself, its active metabolite 9-hydroxyrisperidone, and the closely related drug paliperidone all share structural features with fentanyl that cause antibody cross-reactivity. The underlying mechanism involves non-specific antibody binding to structural motifs that fentanyl and these antipsychotics have in common, producing a signal even when no fentanyl is present.

2Psychiatry Research Case Reports. False-positive fentanyl urine screening during treatment with paliperidone: a case report

Ziprasidone, another antipsychotic, has also been implicated. Researchers have noted that because of its structural similarity to risperidone, ziprasidone can produce the same kind of false-positive fentanyl result on urine drug screens.

3PubMed. A false positive fentanyl result on urine drug screen in a patient treated with ziprasidone

Trazodone, a widely prescribed antidepressant commonly used as a sleep aid, is another major player. A study of veterans who received false-positive fentanyl results found that trazodone had been prescribed to over 82% of them. Even at a facility that used a higher immunoassay cutoff designed to reduce false positives, trazodone was prescribed in nearly 78% of false-positive cases. While this was a retrospective study that could not prove causation, the pattern strongly suggested that trazodone contributes to false-positive fentanyl results.

4Federal Practitioner. Assessment of False-Positive Fentanyl Results on Urine Drug Screens in Veterans

The clinical overlap here is significant. People in substance use treatment or mental health care are among the populations most likely to be both drug-tested regularly and prescribed antipsychotics or trazodone. A false-positive fentanyl result in these settings can have outsized consequences, from losing access to medication-assisted treatment to legal repercussions in criminal justice programs.

Labetalol and Pregnancy

One of the more surprising triggers is labetalol, a blood pressure medication commonly given to pregnant women with hypertensive disorders like preeclampsia. Case reports have documented that labetalol treatment during pregnancy can produce a presumptive positive fentanyl result on urine immunoassays.

5PubMed. False-positive Fentanyl Urine Detection after Initiation of Labetalol Treatment for Hypertension in Pregnancy: A Case Report

This is particularly concerning because drug screening in labor and delivery settings has become routine in many hospitals. A pregnant woman who tests positive for fentanyl may face child protective services involvement, separation from her newborn, or criminal investigation. When the positive result is actually caused by a blood pressure medication that her own doctor prescribed, the consequences are both unjust and avoidable. Clinicians in obstetric settings need to be aware of this cross-reactivity and order confirmatory testing before acting on a presumptive positive.

Diphenhydramine and Other Over-the-Counter Substances

You do not need a prescription to encounter a false-positive fentanyl trigger. Diphenhydramine, the active ingredient in Benadryl, has been shown to cause false positives on fentanyl test strips at high enough concentrations. Laboratory testing found that diphenhydramine, along with methamphetamine and MDMA, produced false-positive results on fentanyl test strips at concentrations at or above 1 mg/mL.

6PubMed Central. High concentrations of illicit stimulants and cutting agents cause false positives on fentanyl test strips

A separate laboratory evaluation confirmed this, finding that diphenhydramine, lidocaine, MDMA, and methamphetamine all caused false positives with fentanyl test strips.

7PubMed Central. Testing the test strips: laboratory performance of fentanyl test strips

The diphenhydramine finding has real-world significance beyond allergy medication. Diphenhydramine is a common cutting agent in heroin, meaning it is mixed in to bulk up the product or mimic sedative effects. When people who use drugs test their supply with fentanyl test strips, the diphenhydramine mixed into the sample can trigger a false positive, making the result unreliable unless the sample is diluted more than standard instructions suggest. The same issue applies to lidocaine, another cutting agent often found mixed into street drug supplies.

Why Fentanyl Test Strips in Harm Reduction Are Different

Fentanyl test strips, widely distributed by harm reduction organizations for people to check whether their drug supply contains fentanyl, use the same immunoassay technology as clinical urine screens. That means they share the same vulnerability to false positives. But the practical context changes the stakes entirely.

In a clinical drug test, a false positive leads to a wrong accusation. With a test strip used by someone checking their drugs, a false positive leads them to believe their supply contains fentanyl when it may not. This could cause them to discard a supply that was actually fentanyl-free, or it could undermine their trust in the strips altogether, leading them to ignore future positive results. One study found that false positives occurred not only from substances like methamphetamine and MDMA at high concentrations, but also when other drugs like cocaine, oxycodone, tramadol, and heroin were present in the sample.

8PubMed Central. Validation of a lateral flow chromatographic immunoassay for the detection of fentanyl in drug samples

The practical fix is dilution. When street drug samples are dissolved in more water before being tested with a strip, the concentration of the interfering substance drops below the level that triggers cross-reactivity. Many harm reduction organizations now recommend diluting samples more than the instructions on the strip packaging suggest.

The Cutoff Problem

Every immunoassay has a cutoff concentration: a threshold above which the test reads “positive” and below which it reads “negative.” The lower the cutoff, the more sensitive the test is to fentanyl, but the more likely it is to pick up trace amounts of cross-reacting substances. Different labs, hospitals, and testing programs use different cutoffs, which means the same urine sample can test positive in one facility and negative in another.

Research has shown that raising the immunoassay cutoff from 1.0 to 5.0 ng/mL would convert false positives caused by iatrogenic fentanyl exposure (meaning fentanyl given by healthcare providers during surgery or procedures) into negative results, while still catching positive results from illicit fentanyl use.

9PubMed. Evaluating the impact of fentanyl immunoassay cutoff concentrations in emergency department, maternal, and neonatal populations

This has major implications for hospitals that test emergency department patients, newborns, or mothers around the time of delivery. A mother who received fentanyl as part of legitimate anesthesia during labor may test positive on a low-cutoff screen afterward, potentially triggering unnecessary child welfare investigations. Adjusting the cutoff to account for medical fentanyl use is one of the most straightforward ways to reduce false positives without changing the test itself.

Not All Test Kits Are Created Equal

The commercial market for fentanyl immunoassays is crowded, and different kits vary substantially in what they detect and what they falsely flag. A pilot study evaluating 19 commercially available kits across 30 fentanyl analogs and metabolites found wide performance differences. Most kits could detect standard fentanyl and closely related analogs, but structurally diverse compounds were often missed. Carfentanil, the extraordinarily potent veterinary opioid, was only picked up by kits specifically designed for it.

10PubMed. Detection of 30 Fentanyl Analogs by Commercial Immunoassay Kits

Comparing specific platforms illustrates the variation. When 58 fentanyl analogs were tested against two widely used immunoassay systems, one detected 51 of 58 analogs while the other detected 57 of 58 at comparable concentrations. The less-sensitive assay was particularly poor at recognizing analogs with modifications to the N-alkyl chain or the piperidine ring, while the other assay handled those variations with much less difficulty.

11PubMed. Detection of 58 fentanyl analogs using ARK fentanyl II and Immunalysis fentanyl immunoassays

This variability means that the specific test brand your hospital or lab uses affects both what it will miss and what it might falsely flag. Two patients with identical urine could get different results depending on which assay was run. The inconsistency is one reason experts push for confirmatory mass spectrometry testing before any clinical or legal decision is made based on a positive screen.

The Bupivacaine Problem in Newborn Testing

A particularly tricky interference occurs in neonatal drug testing. Bupivacaine, a local anesthetic commonly used in epidurals during labor, gets metabolized into a compound called N-desbutylbupivacaine (NDB). This metabolite can interfere with the detection of norfentanyl, the primary metabolite labs look for when testing whether someone has been exposed to fentanyl.

In a large evaluation of neonatal urine samples, nearly 83% of samples that contained NDB showed interference that made norfentanyl results unreliable.

12Clinical Chemistry. Evaluation of Bupivacaine Metabolite Interference With Norfentanyl in a Liquid Chromatography Tandem Mass Spectrometry Assay in Neonatal Urine The good news is that this interference affects norfentanyl detection specifically; results for parent fentanyl itself appear to remain reliable even when NDB is present.

13American Journal of Clinical Pathology. Evaluation of N-desbutylbupivacaine Interference in Fentanyl/Norfentanyl Detection in Three Matrices

When a newborn’s urine test is muddied by NDB from their mother’s epidural, some labs have turned to testing umbilical cord samples instead to resolve whether genuine fentanyl exposure occurred. About 7.5% of cord samples matching urine samples with NDB interference tested positive for fentanyl, which means the vast majority of interfered results would have been resolved as negative with this alternative specimen type.

12Clinical Chemistry. Evaluation of Bupivacaine Metabolite Interference With Norfentanyl in a Liquid Chromatography Tandem Mass Spectrometry Assay in Neonatal Urine

When Fentanyl Is Real but Below the Threshold

Not every “false positive” is truly false. Some occur because fentanyl is genuinely present in the sample but at concentrations too low to confirm with advanced testing methods. One study using a norfentanyl-specific immunoassay found that about half of low-positive specimens contained detectable norfentanyl by mass spectrometry but had fentanyl concentrations below 1 ng/mL. Only six of those were positive on all three immunoassays tested.

14The Journal of Applied Laboratory Medicine. Performance of a Norfentanyl Immunoassay in Specimens with Low Concentrations of Fentanyl and/or Norfentanyl

These gray-zone results are clinically ambiguous. They could represent genuine but very low-level fentanyl exposure, passive environmental exposure, or the tail end of prior medical fentanyl use that is slowly clearing the body. The immunoassay sees something real, but the amount is too small for the confirmation test to definitively call it positive. In practice, these cases are often reported as “unconfirmed positives,” which can be just as consequential for the patient as a clear positive if the result is not interpreted carefully.

Emerging Synthetic Opioids and Detection Gaps

The illicit opioid landscape is shifting, and the testing technology is trying to keep up. A comprehensive evaluation tested four commercial immunoassays against 216 fentanyl analogs and synthetic opioids. All four assays detected 106 of the 216 compounds, but 28 opioids were missed by every assay, and 17 of those were emerging synthetic opioids that have only recently appeared in the drug supply.

15PubMed. Determining the detection of 216 fentanyl analogs and synthetic opioids and predicting epitopes using four commercial immunoassays

At the lowest concentration tested, the detection range across assays was enormous: one assay flagged just 5 of the 216 compounds, while the best-performing assay detected 74. This means the choice of testing platform is not just a matter of false positives. It also determines whether genuinely dangerous substances are detected at all. An assay that is more sensitive to a broader range of analogs may also be more prone to cross-reactivity with non-opioid substances, creating an inherent tradeoff between catching everything dangerous and avoiding false alarms.

What You Can Do About a False-Positive Result

If you or someone you know receives a positive fentanyl screening result and there is reason to believe it may be false, the single most important step is to request confirmatory testing by liquid chromatography-tandem mass spectrometry. This method physically separates and identifies the molecules in the sample, making cross-reactivity essentially a non-issue. It can distinguish fentanyl from risperidone, trazodone, diphenhydramine, or any other interfering compound with near-certainty.

Bringing a complete medication list to any drug test is also valuable. If you are taking risperidone, paliperidone, ziprasidone, trazodone, labetalol, or any medication with known cross-reactivity, flagging it before the test gives the clinician context to interpret the result appropriately. Some facilities will note these medications in advance and proceed directly to confirmatory testing rather than relying on the immunoassay screen.

For people in substance use treatment programs or criminal justice settings, where a positive fentanyl test can result in discharge from treatment or sanctions, understanding the limits of immunoassay testing is worth bringing up proactively. Many clinicians and case managers are not fully aware of the growing list of cross-reactive medications, and a conversation about the known limitations of the screening test can sometimes prevent a false positive from snowballing into real harm.